Table 3. Univariate analysis of demographic and clinical characteristics affecting the median OS in stage IV NSCLC patients with EGFR-TKIs therapy.
| Characteristics | No. of cases | Median OS (months, 95% CI) | P | |
|---|---|---|---|---|
| Overall | 94 | 31 (26.18–35.82) | - | |
| Gender | Male | 49 | 31 (17.46–44.54) | 0.769 |
| Female | 45 | 30 (24.26–35.75) | ||
| Age (years) | ≤ 60 | 58 | 31 (23.51–38.49) | 0.66 |
| > 60 | 36 | 30 (20.92–39.08) | ||
| Smoking status | No | 73 | 34 (29.39–38.12) | 0.026 |
| Yes | 21 | 24 (16.86–31.14) | ||
| Pathologic type | Adenocarcinoma | 86 | 31 (25.89–36.11) | 0.638 |
| Non-adenocarcinoma | 8 | 24 (6.45–41.56) | ||
| Brain metastasis | Yes | 33 | 24 (20.93–27.07) | 0.021 |
| No | 61 | 35 (27.93–42.07) | ||
| Timing of targeted therapy | First line | 28 | 33 (24.02–41.98) | 0.819 |
| Second or higher line | 66 | 31 (22.06–39.94) | ||
| ECOG score | 0–1 | 54 | 41 (23.14–48.86) | 0 |
| ≥ 2 | 40 | 23 (15.82–30.18) | ||
| Combination with chemotherapy | Yes | 82 | 30 (23.6–36.41) | 0.434 |
| No | 12 | 34 (31.89–36.11) | ||
| Type of EGFR mutation (64 cases) | 19del | 37 | 34 (22.63–45.37) | 0.158 |
| 21L858R | 27 | 23 (13.09–32.9) |